 SAN FRANCISCO, CA ACCESSWIRE May 20, 2021 Jaguar Health, Inc. NASDAQ:JAGX Jaguar or the Company today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea CRD by Napo Pharmaceuticals, Inc. Napo, Jaguars wholly owned subsidiary, and Napos collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology ASCO Annual Meeting, which will be held virtually from June 4-8, 2021. In addition, two CRD-related abstracts from Napo and its collaborators have been accepted for online publication at ASCO. 